Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies1393
  • 7D2.2%
  • 3M-5.6%
  • 1Y11.9%
  • YTD-3.5%

In the last week, the Healthcare industry is up 1.6%, with Thermo Fisher Scientific up 7.7%. This means that the industry has gained 11% over the past year. Earnings are forecast to grow by 16% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Apr 2026US$6.3tUS$3.3tUS$127.2b23.4x49.3x1.9x
Fri, 13 Mar 2026US$6.4tUS$3.3tUS$124.5b24.2x51.1x1.9x
Sun, 08 Feb 2026US$6.6tUS$3.3tUS$125.4b27.1x52.4x2x
Tue, 06 Jan 2026US$6.5tUS$3.2tUS$135.6b25.8x47.8x2x
Thu, 04 Dec 2025US$6.4tUS$3.2tUS$133.5b25.7x48x2x
Sat, 01 Nov 2025US$5.9tUS$3.1tUS$134.3b26.3x44.3x1.9x
Mon, 29 Sep 2025US$5.7tUS$3.1tUS$137.6b23.6x41.1x1.8x
Wed, 27 Aug 2025US$5.7tUS$3.1tUS$137.2b23.5x41.2x1.8x
Fri, 25 Jul 2025US$5.6tUS$3.0tUS$129.1b25.1x43.4x1.8x
Sun, 22 Jun 2025US$5.5tUS$3.0tUS$127.4b23.7x42.8x1.8x
Tue, 20 May 2025US$5.4tUS$3.0tUS$126.1b24x42.9x1.8x
Thu, 17 Apr 2025US$5.4tUS$2.6tUS$90.0b24.8x59.5x2x
Sat, 15 Mar 2025US$5.6tUS$2.6tUS$74.8b26.6x74.8x2.1x
Mon, 10 Feb 2025US$5.9tUS$2.6tUS$89.8b26.5x65.5x2.2x
Wed, 08 Jan 2025US$5.8tUS$2.9tUS$79.3b27.7x73.4x2x
Fri, 06 Dec 2024US$6.2tUS$2.9tUS$77.4b28.7x79.5x2.1x
Sun, 03 Nov 2024US$6.2tUS$2.9tUS$71.3b28.4x86.4x2.1x
Tue, 01 Oct 2024US$6.2tUS$2.9tUS$70.6b30.3x87.9x2.1x
Thu, 29 Aug 2024US$6.3tUS$2.8tUS$54.0b31.6x116.3x2.2x
Sat, 27 Jul 2024US$6.3tUS$2.8tUS$61.0b31.6x104x2.2x
Mon, 24 Jun 2024US$6.2tUS$2.8tUS$62.5b30x99.2x2.2x
Wed, 22 May 2024US$6.2tUS$2.8tUS$64.2b30.7x96.7x2.2x
Fri, 19 Apr 2024US$5.9tUS$2.8tUS$84.4b30x70.2x2.1x
Sun, 17 Mar 2024US$6.2tUS$2.8tUS$84.5b31.5x73.7x2.2x
Tue, 13 Feb 2024US$6.2tUS$2.8tUS$76.4b32x81.2x2.2x
Thu, 11 Jan 2024US$6.4tUS$2.8tUS$90.1b32.3x70.9x2.3x
Sat, 09 Dec 2023US$6.0tUS$2.8tUS$91.4b29.4x65.1x2.1x
Mon, 06 Nov 2023US$5.7tUS$2.8tUS$88.4b26.7x65x2x
Wed, 04 Oct 2023US$5.8tUS$2.8tUS$98.2b26.5x59.2x2.1x
Fri, 01 Sep 2023US$6.1tUS$2.8tUS$98.8b27.7x61.6x2.2x
Sun, 30 Jul 2023US$6.1tUS$2.8tUS$115.6b28x52.5x2.2x
Tue, 27 Jun 2023US$6.0tUS$2.7tUS$109.8b26.6x54.5x2.2x
Thu, 25 May 2023US$5.9tUS$2.7tUS$110.9b24x53x2.2x
Sat, 22 Apr 2023US$6.0tUS$2.5tUS$117.6b24.9x51x2.4x
Price to Earnings Ratio

51x


Total Market Cap: US$6.0tTotal Earnings: US$117.6bTotal Revenue: US$2.5tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 48.8x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 2.6% per year over the last three years.
  • Revenues for these companies have grown 9.6% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market4.44%
Healthcare2.18%
Life Sciences5.83%
Biotech3.82%
Medical Equipment2.92%
Healthcare Services0.90%
Pharma0.60%
Healthtech-4.21%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 55.6x.
    • Analysts are expecting annual earnings growth of 16.0%, which is higher than its past year's earnings growth of 7.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 23% over the next 5 years.
  • However this is lower than its past earnings growth rate of 50% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 11% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$527.227.7%
+US$14.0b		19.6%PE29.2x
RVMD Revolution MedicinesUS$147.0152.7%
+US$10.1b		304.8%PB17.9x
ABBV AbbVieUS$210.261.9%
+US$6.9b		18.9%PE88.8x
AMGN AmgenUS$350.953.2%
+US$5.9b		18.8%PE24.6x
UNH UnitedHealth GroupUS$314.192.1%
+US$5.9b		-46.2%PE23.7x

Latest News

RVMD
US$147.01
Revolution Medicines
7D
52.7%
1Y
304.8%
TMO
US$527.22
Thermo Fisher Scientific
7D
7.7%
1Y
19.6%
LLY
US$922.50
Eli Lilly
7D
-0.9%
1Y
21.8%
VEEV
US$159.09
Veeva Systems
7D
-7.8%
1Y
-28.6%
GH
US$86.40
Guardant Health
7D
-7.4%
1Y
92.6%
SYK
US$345.88
Stryker
7D
4.2%
1Y
-0.3%
UNH
US$314.19
UnitedHealth Group
7D
2.1%
1Y
-46.2%

UNH: Medicare Policy Debate Will Support Post 2026 Earnings Resilience

Analysts have modestly revised their UnitedHealth Group price targets higher, with adjustments framed around slightly stronger long term profit margin assumptions, a small uptick in expected revenue growth, and mixed commentary on future margin pressure and policy risks. Analyst Commentary Recent research on UnitedHealth Group points to a split between caution around policy and margin headwinds and a more constructive stance on long term earnings power and capital deployment.
ABBV
US$210.26
AbbVie
7D
1.9%
1Y
18.9%
REGN
US$755.51
Regeneron Pharmaceuticals
7D
-0.6%
1Y
35.4%
ABT
US$101.05
Abbott Laboratories
7D
-0.8%
1Y
-19.9%
EW
US$78.20
Edwards Lifesciences
7D
-3.3%
1Y
10.5%

EW: 2026 LAA Closure Expansion Will Support Upside Repricing

Analysts have nudged their fair value target for Edwards Lifesciences slightly lower to about $96.93, reflecting updated assumptions on discount rates, revenue growth, profit margins, and future P/E following a mix of recent price target cuts and raises across the Street. Analyst Commentary Recent research takes on Edwards Lifesciences point to a mixed but generally engaged stance from the Street, with both upgrades and target changes feeding into the updated fair value view.
AMGN
US$350.95
Amgen
7D
3.2%
1Y
18.8%
CVS
US$77.62
CVS Health
7D
-0.8%
1Y
12.6%

CVS: Medicare Advantage Turnaround Will Support Future Earnings Recovery

Analysts have trimmed the average CVS Health price target by a few dollars to around the mid $90s. This reflects slightly softer revenue growth assumptions, modestly higher margin expectations, and updated views on Medicare Advantage and regulatory risks following recent CMS and FTC related commentary.
INSM
US$153.40
Insmed
7D
-4.2%
1Y
118.5%
DHR
US$198.61
Danaher
7D
4.0%
1Y
4.6%

Danaher: A Great Way To Play Healthcare For Long-Term Dividend Growth Investors

Apr 06
ISRG
US$467.22
Intuitive Surgical
7D
3.2%
1Y
-4.3%

ISRG: Procedure Expansion And Sector Recovery Will Drive 2026 Upside

Analysts have adjusted Intuitive Surgical's price targets in a mixed but generally constructive way, with revisions ranging from cuts at UBS to $550 and $570 to higher targets at firms like Goldman Sachs at $714 and Bernstein at $740. These changes reflect updated views on growth, margins, and the valuation framework around a future P/E near 65.5x.